← All peptidesPDA-V1 attestation Citations
warningBioGate · AMBERGrade B
Liraglutide
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGGLP-1 receptor agonist with ~13 hour half-life via albumin-binding palmitoyl chain; daily SC dosing for glycemic control and weight loss.
γGlu-C16 palmitoyl sidechain @ K20
MW
3751.20
Length
31aa
Posterior
26.6%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · γGlu-C16 palmitoyl sidechain @ K20
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 1
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
1
Participants
472
Mean Δ
-0.66
Δ HRV ms (8-week) · 95% CI [-2.12, 0.8]
IPNFT · Molecule IPNFT V2Solana
Liraglutide
621a83…37651aRoyalty cascade
6.87%
Holders
94
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2015 · N Engl J Med
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)
Pi-Sunyer X et al.